Navigation Links
Schering-Plough Reports Financial Results for Third Quarter of 2007
Date:10/22/2007

2007 2006 % 2007 2006 %

GLOBAL PHARMACEUTICALS $2,291 $2,087 10% $7,209 $6,350 14%

REMICADE 426 317 34% 1,193 902 32%

NASONEX 242 221 10% 821 691 19%

PEGINTRON 221 206 7% 672 629 7%

TEMODAR 215 179 20% 627 513 22%

CLARINEX / AERIUS 171 171 - 625 557 12%

CLARITIN RX 83 74 12% 297 279 7%

INTEGRILIN 78 82 (4%) 241 244 (1%)

AVELOX 78 63 24% 269 201 34%

CAELYX 64 52 23% 191 156 22%

INTRON A 61 57 7% 176 180 (2%)

REBETOL 60 72 (16%) 206 237 (13%)

SUBUTEX / SUBOXONE 55 51 8% 163 152 7%

PROVENTIL / ALBUTEROL CFC 52 45 16% 166 148 12%

ELOCON 40 36 11% 119 108 10%

ASMANEX 36 28 30% 121 68 79%

FORADIL 25 22 13% 77 66 16%

NOXAFIL 24 6 N/M 60 10 N/M

Other Pharmaceuticals 360 405 (11%) 1,185 1,209 (2%)

CONSUMER HEALTH CARE 273 259 5% 1,012 918 10%

OTC 162 138 17% 521 440 18%

OTC CLARITIN 104 95 9% 368 318 16%

Foot Care 92 92 - 272 270 1%

Sun Care 19 29 (33%) 219 208 6%

ANIMAL HEALTH
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Asmanex Twisthaler launched by Schering-Plough for treatment of asthma
2. Autopsy reports could be valuable and informative
3. China reports declining number of SARS Cases
4. Russia Reports First SARS Case
5. Research reports that c-section deliveries are rising
6. Jharkhand reports 13,000 Malaria cases
7. Uganda Reports Failure To Contain Sleeping Sickness
8. WHO reports 36 million deaths world wide due to chronic diseases
9. Reports of Hantavirus infection in India raise concerns
10. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
11. China Reports Yet Another Bird Flu Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Serial entrepreneur, Paul Mata, spent the early part of ... people, in 2008 he suffered extreme financial hardship and lost ... carefully studied the difference between people who have sustainable and ... the knowledge he acquired, he was able to use what ... but also grow his clients' personal and financial assets while ...
(Date:7/30/2014)... WHAT: , Resistance to artemisinin, the main drug ... Asia, among the Plasmodium falciparum ( ... and is likely caused by a genetic mutation ... artemisinin-based combination therapyas opposed to a standard three-day ... cases, according to findings published today in the ...
(Date:7/30/2014)... 2014 Volunteers from the Church of ... abuse this summer with massive distribution of Truth ... find these volunteers on Strøget, the famous Copenhagen walking ... its shopping and its ambiance, some quarter of a ... summer day. , These activities are part of ...
(Date:7/30/2014)... Pennsylvania (PRWEB) July 30, 2014 Visitors ... have contributed over $8,500 to ensure its protection. Bob ... presents a check to the Delaware Highlands Conservancy for ... program. The small $2-per-stay donations add up fast, as ... of the Upper Delaware River Region. , The Kiesendahl ...
(Date:7/30/2014)... NJ. July 30, 2014. A new network of 25 ... Stroke Trials Network (NIH StrokeNet) is working to ... U.S. Despite advances of the last two decades, ... stroke causes death or disability for 795,000 Americans. The ... of the population. , To accelerate the pace ...
Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2
... , ... ... ... ...
... to physical function but also extend to neurological function, according ... Journals of Gerontology Series A: Biological and Medical Sciences ... collection of ten articles highlighting new findings related to obesity ... of improved medical management of cardiovascular disease is that many ...
... procedures annually may improve life expectancy, study finds ... with both mammography and MRI appears to be a ... high risk for breast cancer, U.S. researchers say. , ... at Massachusetts General Hospital in Boston, and colleagues used ...
... physician shortages, researchers say, , TUESDAY, Feb. 23 (HealthDay News) -- ... a sharp decline in the average number of hours they work ... 1996, the average work week of doctors remained steady, but between ... work dropped nearly four hours a week -- from 54.9 to ...
... ... ... , ... , , , ...
... ... ... ... , ...
Cached Medicine News:Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 2Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 3Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 4Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 5Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 6Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 7Health News:Overweight middle-aged adults at greater risk for cognitive decline in later life 2Health News:Mammogram Plus MRI Cost-Effective in High-Risk Women 2Health News:Doctors Working Less, Earning Less 2Health News:Doctors Working Less, Earning Less 3Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 2Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 3Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 4Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 5Health News:Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis 2Health News:Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis 3
(Date:7/30/2014)... N.J. , July 30, 2014  InnoPharma, Inc. ... Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in ... agitation and disturbed behaviors in patients with schizophrenia or ... this generic injectable drug, InnoPharma has entered into an ... Sandoz Canada will make, use, sell, market and ...
(Date:7/30/2014)... Mass. , July 30, 2014 Cynosure, ... laser- and light-based aesthetic treatments for non-invasive and minimally invasive ... Executive Vice President, Chief Operating Officer and Chief Financial Officer ... effective August 1, 2014.  Baker, 53, will continue to serve ... Michael Davin , who remains Chairman and Chief Executive ...
(Date:7/30/2014)... DIEGO , July 30, 2014  Eisai Inc. and ... that an article based on post-hoc analyses from the three ... While on Lorcaserin, Diet, and Exercise as a Predictor of ... issue of Obesity , the official peer reviewed journal ... to identify whether there is an early treatment milestone that ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... N.Y., Feb. 6, 2012 /PRNewswire-iReach/ -- SalesCongo ... announced today it has named Kenneth R. Kaisen as its ... as a technology industry veteran with over 25 years of ... Vertis Communications, a marketing communications company. He was previously CEO ...
... (NYSE: CBM, "Cambrex") is pleased to announce that Greg Sargen, ... presentation on the Company at the UBS 22nd Annual Global ... EST at the Grand Hyatt New York, New York City. ... Cambrex website http://www.cambrex.com in the Investors section of ...
Cached Medicine Technology:SalesCongo Names Ken Kaisen CEO 2
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
The pediatric blanket provides full coverage for pediatric patient care. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also red...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
Medicine Products: